Business
Viking Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, April 3, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the
About this update from Viking Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, April 3, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. (\"Viking\") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing of its previously announced underwritten public offering of 19,828,300 shares of its common stock at a public offering price of $14.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 2,586,300 additional shares of common stock. The gross proceeds to Viking from this offering are approximately $287.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses.\n\n \n \n \n \n \n \n\n \nWilliam Blair & Company, L.L.C. acted as lead book-running manager for the offering and Raymond James & Associates, Inc. acted as joint book-running manager for the offering. Truist Securities, Inc., BTIG, LLC, Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC also acted as bookrunners for the offering. Maxim Group LLC, Roth Capital Partners, LLC and Laidlaw & Company (UK) Ltd. acted as co-managers for the offering.\nViking currently intends to use the net proceeds from the offering for continued development of its VK2809, VK2735 and VK0214 programs and for general research and development, working capital and general corporate purposes.\nThe securities described above were offered by Viking pursuant to a shelf registration statement on Form S-3 (File No. 333-258231), previously filed with the Securities and Exchange Commission (the \"SEC\") on July 28, 2021, and declared effective on August 11, 2021. A final prospectus supplement and accompanying prospectus related to the offering was filed with the SEC on March 31, 2023 and is available on the SEC's website at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting William Blair & Company, L.L.C. at 150 North Riverside Plaza, Chicago, Illinois 60606, Attention: Prospectus Department, by telephone at (800) 621-0687, or by email at [email protected]. These documents may also be obtained by contacting Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, by telephone at (800) 248-8863, o...